产品: METTL3 抗体
货号: DF12020
描述: Rabbit polyclonal antibody to METTL3
应用: WB IHC
文献验证: WB
反应: Human, Mouse, Rat
预测: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
蛋白号: Q86U44
RRID: AB_2844825

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
METTL3 Antibody detects endogenous levels of total METTL3.
RRID:
AB_2844825
引用格式: Affinity Biosciences Cat# DF12020, RRID:AB_2844825.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

adoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase; IME4; M6A; Methyltransferase like protein 3; Methyltransferase-like protein 3; METTL3; mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase; mRNA m(6)A methyltransferase; MT-A70; MTA70; MTA70_HUMAN; N6 adenosine methyltransferase 70 kDa subunit; N6-adenosine-methyltransferase 70 kDa subunit;

抗原和靶标

免疫原:

A synthesized peptide derived from human METTL3

基因/基因ID:

文献引用

1). MiR-29a-3p Improves Acute Lung Injury by Reducing Alveolar Epithelial Cell PANoptosis. Aging and Disease, 2022 (PubMed: 35656115) [IF=7.0]

Application: WB    Species: Mouse    Sample: lung tissue

Figure 2. METTL3-mediated m6A modification stabilizes the expression of miR-29a-3p. (A) The level of total m6A in the lung tissue of ALI mouse model. (B) m6A RIP detects the m6A level of pri-miR-29a in the lung tissue of ALI mouse model. (C) RT-qPCR detection of METL3 expression in the lung tissue of ALI mouse model. (D) Western blot analysis for the expression of METTL3 in the lung tissue of ALI mouse model. (E) Western blot analysis for the expression of METTL3 in A549 cells after siRNA transfection. (F) RT-qPCR analysis for the level of miR-29a-3p in A549 cells after METTL3 siRNA transfection. *** p <0.001.

2). Inhibition of METTL3 promotes mesangial cell mitophagy and attenuates glomerular damage by alleviating FOSL1 m6A modifications via IGF2BP2-dependent mechanisms. Biochemical pharmacology, 2025 (PubMed: 40081768) [IF=5.3]

3). METTL3 contributes to slow transit constipation by regulating miR‐30b‐5p/PIK3R2/Akt/mTOR signaling cascade through DGCR8. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022 (PubMed: 36068012) [IF=3.7]

4). METTL3 Promotes Osteosarcoma Metastasis via an m6A-dependent Epigenetic Activity of CBX4. Frontiers in bioscience (Landmark edition), 2024 (PubMed: 38538251) [IF=3.3]

5). METTL3 Promotes the Growth and Invasion of Melanoma Cells by Regulating the lncRNA SNHG3/miR-330-5p Axis. Cell transplantation, 2023 (PubMed: 37606168) [IF=3.2]

Application: WB    Species: human    Sample:

Figure 1. Elevated expression of METTL3 is associated with poor survival in patients with melanoma. (A) TCGA analysis of the expression of METTL3 in 474 non-paired melanoma samples. (B) RT-qPCR analysis of the expression levels of METTL3 in 10 pair-matched melanoma tissue samples. (C, D) Western blot analysis of the expression of METTL3 in 10 pair-matched melanoma samples. (E) Kaplan–Meier analysis of the association of METTL3 expression with overall survival and tumor recurrence in patients with melanoma. GAPDH: glyceraldehyde-3-phosphate dehydrogenase; METTL3: methyltransferase 3; RT-qPCR: real-time quantitative polymerase chain reaction; TCGA: The Cancer Genome Atlas.

6). METTL3-Mediated m6A Modification of lncRNA MALAT1 Facilitates Prostate Cancer Growth by Activation of PI3K/AKT Signaling. Cell transplantation, 2022 (PubMed: 36073002) [IF=3.2]

Application: WB    Species: human    Sample: DU145 and 22RV1 cells

Figure 1. Upregulation of METTL3 is associated with tumor recurrence in patients with PCa. (A) TCGA analysis of the expression levels of METTL3 in 52 pair-matched and 484 non-paired PCa tissue samples. (B, C) qRT-PCR and Western blot analysis of the expression levels of METTL3 in 10 pair-matched PCa tissue samples. (D) TCGA cohort analysis of the association of METTL3 with the prognosis in PCa with patients. PCa: prostate cancer; qRT-PCR: quantitative real-time polymerase chain reaction.

7). METTL3/14 and IL‐17 signaling contribute to CEBPA‐DT enhanced oral cancer cisplatin resistance. ORAL DISEASES, 2023 (PubMed: 34807506) [IF=2.9]

8). Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023 (PubMed: 36484954) [IF=2.8]

9). METTL3-Mediated m6A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis. Cancer biotherapy & radiopharmaceuticals, 2024 (PubMed: 39263746) [IF=2.4]

10). HIF-1α-induced upregulation of m6A reader IGF2BP1 facilitates peripheral nerve injury recovery by enhancing SLC7A11 mRNA stabilization. In vitro cellular & developmental biology. Animal, 2023 (PubMed: 37783915) [IF=1.5]

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.